AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ARXS

Sealfon Ross Bradley sold $783K of ARXS

Sealfon Ross Bradley (See Remarks) sold 15,000 shares of Arxis, Inc. (ARXS) at an average of $52.23 ($51.44–$53.03, $0.78M total) across 3 trades on 2026-11-11.

Original reporting
SEC EDGAR · Sealfon Ross Bradley
Published Nov 13, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARXS
Bearish
medium confidence
Mentioned
$ARXS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARXSBearishLow
01

Why it matters

The disclosed sale adds a modest negative signal for ARXS, but the overall market impact is limited.

02

Market read

Insider sell of $783K may prompt short‑term price pressure for ARXS.

03

What to watch

Potential upcoming clinical data or financing needs that prompted the insider to liquidate shares.

Relevance 5/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; ARXS is a Nasdaq‑listed biotech.

Company-level read

Ticker impact

$ARXSBearishMedium confidence
Context

Officer Sealfon Ross Bradley sold 15,000 shares for $783,393.78 in open‑market trades on 2026‑11‑11.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $783K sale by an officer is material for a micro‑cap biotech and typically triggers short‑term selling pressure.

Market effects

Sector

Minimal impact on the broader biotech sector; the sale is company‑specific.

Regional

No regional effect; confined to ARXS shareholders.

Global

Low; does not affect global markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • company
    Arxis, Inc.

    Biotech company listed on Nasdaq under ticker ARXS.

  • person
    Sealfon Ross Bradley

    Officer of Arxis, Inc. who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARXS insider trading history →

Related articles

MedAI 8/10

Arxis Q3 2026 presentation: 67% EBITDA jump, stock falls 10%

Arxis reported Q3 2026 revenue of $564M (+36% YoY) and adjusted EBITDA of $256M (+67% YoY), raising full-year guidance but warning of margin normalization. Shares fell 10% post-earnings, citing concerns over growth sustainability and high valuation. The company plans acquisitions and expects 2027 revenue of $2.4B-$2.5B.

investing.com
Med

Quarterly profit swung from a $10 million loss to $84 million at Arxis.

Arxis reported Q3 2026 revenue of $564 million, up 36% YoY, with net income of $84 million, compared to a $10 million loss in Q3 2025. Adjusted EBITDA rose 67% to $256 million. The company raised full-year 2026 guidance and introduced 2027 guidance, anticipating continued growth and margin expansion. Recent acquisitions include Omnetics, Schatz Bearing, and StratEdge.

stocktitan.net
$ARXSHigh

RBC Capital upgrades Arxis stock rating on M&A activity, pricing

RBC Capital upgraded Arxis Inc. (NASDAQ:ARXS) to Outperform, raising its price target to $60.00. The firm cited strong M&A activity and pricing strength in aerospace and defense markets. Arxis reported 25% revenue growth to $501 million in Q2 2026, with adjusted EBITDA up 38% to $211 million. The company raised its full-year outlook, reflecting broad-based demand and strategic acquisitions.

investing.com
$ARXSHighAI 9/10

Arxis (ARXS) Closed an Approximately $770 Million Connector Acquisition. Is its Roll-Up Still Disciplined?

Arxis, Inc. (ARXS) completed the acquisition of Omnetics Connector Corporation for approximately $770 million, issuing 13.35 million Class A shares. The deal is part of Arxis's roll-up strategy, with Omnetics joining its Electronic Components segment. The company's Q2 revenue grew 25% to $500.7 million, with adjusted EBITDA up 38% to $211.5 million. The acquisition's valuation is based on estimated fiscal-2027 adjusted EBITDA, raising questions about its disciplined underwriting.

insidermonkey.com
$ARXSMedAI 8/10

Arxis Completes the Acquisition of Omnetics Connector Corporation

Arxis, Inc. (NASDAQ: ARXS) said it completed its acquisition of Omnetics Connector Corporation. The deal was based on an agreed enterprise value of about $770 million, with customary closing adjustments. Arxis issued 13,351,964 shares at closing to Omnetics shareholders, about 3.1% of total common stock, subject to lockups. The combined purchase price multiple with a prior MagCanica deal is about 12x FY27 estimated adjusted EBITDA.

prnewswire.com